Promore Pharma AB (publ) Interim report January - June 2019
April to June · Net sales amounted to 0.7 (0) MSEK. · The operating loss for the period was 7.4 (-10.8) MSEK · Net loss was 7.3 (- 9.8) MSEK, corresponding to earnings per share of SEK -0.36 (-0.48) · Cash flow from operating activities amounted to -6.9 (-8.6) MSEK · Cash and cash equivalents amounted to 19.7 (46.0) MSEK January to June · Net sales amounted to 1.2 (0.1 MSEK). · The operating loss for the period was 12.9 (-18.7) MSEK · Net loss was 12.8 (-17.7) MSEK, corresponding to earnings per share of SEK 0.63 (-0.88) · Cash flow from operating activities